Skip to main content
SpringerLink
Log in

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.

    CAS  Google Scholar 

  2. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325.

    Article  CAS  Google Scholar 

  3. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60.

    Article  CAS  Google Scholar 

  4. Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 2005; 19: 507–512.

    Article  CAS  Google Scholar 

  5. Jorgensen HG, Copland M, Allan EK, Jiang X, Eaves A, Eaves C et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006; 12: 626–633.

    Article  CAS  Google Scholar 

  6. Khorashad JS, Anand M, Marin D, Saunders S, Al-Jabary T, Iqbal A et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006; 20: 658–663.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported by the Leukaemia Research Fund CTAP (UK), Chugai Pharmaceutical Co. Ltd, Chugai Pharma, France and Novartis Pharmaceuticals (UK). We are grateful to Lindsay Mitchell and Karen Stewart for their help with recruitment and assessment of patients. We thank the ‘Délégation à la recherche clinique des Hospices Civils de Lyon’ for their support in setting up this trial in France and Elodie Gadolet, CRA, for her help in collecting the data for the French patients. Drs Steve O'Brien, Heather Jorgensen and Alex McMahon assisted in reviewing the data.

Author information

Authors and Affiliations

  1. Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, UK

    M W Drummond

  2. Section of Experimental Haematology, University of Glasgow, Glasgow, UK

    N Heaney, G Wilson, L McLintock & T L Holyoake

  3. Department of Haematology, Hammersmith Hospital, London, UK

    J Kaeda

  4. Haematology Department, Hôpital Edouard Herriot, Lyon, France

    F E Nicolini

  5. Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK

    R E Clark

  6. Department of Haematology, Western General Hospital, Edinburgh, UK

    P Shepherd

  7. Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, UK

    J Tighe

  8. Institute of Medical Veterinary Science, University of Adelaide, Adelaide, Australia. E-mail: mark.drummond@ggc.scot.nhs.uk,

    T Hughes

Authors
  1. M W Drummond
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Heaney
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Kaeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F E Nicolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R E Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Shepherd
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Tighe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L McLintock
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T L Holyoake
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drummond, M., Heaney, N., Kaeda, J. et al. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia 23, 1199–1201 (2009). https://doi.org/10.1038/leu.2009.43

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.43

  • Springer Nature Limited

This article is cited by

Search

Navigation